Literature DB >> 8137480

Prognosis after hepatic resection in patients with hepatocellular carcinoma, estimated on the basis of the morphometric indices.

Y Kawai1, K Takeshige, M Nunome, H Kuroda, H Suzuki, K Banno, T Koide, H Kobayashi, Y Owa, A Koike.   

Abstract

To determine whether the morphometric indices of hepatocellular carcinoma (HCC) correlated with the prognoses, the microscopic morphometric values for 84 HCC cases treated by hepatic resection were studied using an image analyzer in relation to the survival rate and the gross classification. The mean survival time (MST) was 58 months in cases with a nucleocytoplasmic area ratio (N/C) of less than 0.28; this was significantly longer than the 38-month MST in cases with an N/C of more than 0.28 (P < 0.05). In stage III disease, the MST for cases with an N/C of less than 0.28 was 63 months, which was significantly longer than the MST of 13 months for cases with an N/C of more than 0.28. After relatively noncurative hepatic resection, the MST for cases with an N/C of less than 0.28 was 49 months, and this was significantly longer than the MST of 8 months for cases with an N/C of more than 0.28. The MST was 71 months for cases with a coefficient of variance of the nuclear form factor (NCV) of less than 5.5%, which was significantly longer than the MST of 33 months for cases with an NCV of more than 5.5% (P < 0.05). In stage III disease, the MST was 69 months for cases with an NCV of less than 5.5%, and this was significantly longer than the MST of 29 months for cases with an NCV of more than 5.5% (P < 0.05). In cases with an N/C of less than 0.28, 18% had vascular invasion and 38% had intrahepatic metastases, whereas in those with an N/C of more than 0.28, 62% had vascular invasion and 67% had intrahepatic metastases (P < 0.01, P < 0.05). Based on the results of these morphometric studies on HCC cases treated by hepatic resection, N/C and NCV may be useful as prognostic factors.

Entities:  

Mesh:

Year:  1994        PMID: 8137480     DOI: 10.1007/bf00686663

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Limitations of current preoperative liver imaging techniques for intrahepatic metastatic nodules of hepatocellular carcinoma.

Authors:  T Utsunomiya; T Matsumata; E Adachi; H Honda; K Sugimachi
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Increased DNA synthetic potency of hepatocytes in cirrhotic patients may indicate a super-high risk for hepatocellular carcinoma.

Authors:  K Tarao; A Shimizu; M Harada; S Ohkawa; S Tamai; Y Ito; Y Kuni; S Takemiya; T Okamoto
Journal:  Jpn J Med       Date:  1990 Jul-Aug

4.  Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria.

Authors:  F Kondo; K Wada; Y Nagato; T Nakajima; Y Kondo; N Hirooka; M Ebara; M Ohto; K Okuda
Journal:  Hepatology       Date:  1989-05       Impact factor: 17.425

5.  The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas.

Authors:  T Nonami; K Isshiki; H Katoh; W Kishimoto; A Harada; A Nakao; H Takagi
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

6.  Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection.

Authors:  S C Jwo; J H Chiu; G Y Chau; C C Loong; W Y Lui
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

7.  Significance of multidisciplinary therapy for hepatocellular carcinoma.

Authors:  Y Kawarada; T Imai; M Iwata; H Yokoi; T Noguchi; R Mizumoto
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization.

Authors:  K Tanaka; S Nakamura; K Numata; H Okazaki; O Endo; S Inoue; Y Takamura; M Sugiyama; Y Ohaki
Journal:  Radiology       Date:  1992-11       Impact factor: 11.105

9.  Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial.

Authors:  F Yoshimi; T Nagao; S Inoue; N Kawano; T Muto; T Gunji; S Ohnishi; M Imawari
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

10.  Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy.

Authors:  S Arii; J Tanaka; Y Yamazoe; S Minematsu; T Morino; K Fujita; S Maetani; T Tobe
Journal:  Cancer       Date:  1992-02-15       Impact factor: 6.860

  10 in total
  1 in total

1.  Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth.

Authors:  Uta Rabenhorst; Rasa Beinoraviciute-Kellner; Marie-Luise Brezniceanu; Stefan Joos; Frauke Devens; Peter Lichter; Ralf J Rieker; Jörg Trojan; Hye-Jung Chung; David L Levens; Martin Zörnig
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.